Capricor Therapeutics (LTS:0HTB) Accounts Payable: €3.40 Mil (As of Mar. 2026)


What is Capricor Therapeutics Accounts Payable?

Capricor Therapeutics LTS:0HTB 37 Accounts Payable is €3.40 Mil as of Mar. 2026. GuruFocus rates LTS:0HTB with a GF Score™ of 37/100. The stock has 3 warning signs investors should review.

Capricor Therapeutics's Accounts Payable for the quarter that ended in Mar. 2026 was €3.40 Mil.

Capricor Therapeutics's quarterly Accounts Payable declined from Sep. 2025 (€2.32 Mil) to Dec. 2025 (€1.41 Mil) but then increased from Dec. 2025 (€1.41 Mil) to Mar. 2026 (€3.40 Mil).

Capricor Therapeutics's annual Accounts Payable increased from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€3.14 Mil) but then declined from Dec. 2024 (€3.14 Mil) to Dec. 2025 (€1.41 Mil).

Capricor Therapeutics Accounts Payable Related Terms

Capricor Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Capricor Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Capricor Therapeutics Accounts Payable Chart

Capricor Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 4.56 0.00 3.14 1.41

Capricor Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.86 4.17 2.32 1.41 3.40

Capricor Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €3.40 Mil mean?
Capricor Therapeutics (LTS:0HTB) has a Accounts Payable of €3.40 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Capricor Therapeutics and its competitors.
Is Capricor Therapeutics' Accounts Payable too high?
Capricor Therapeutics' current Accounts Payable is €3.40 Mil. Overall, Capricor Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Capricor Therapeutics' Accounts Payable compare to COAG and DMRA?
Capricor Therapeutics' Accounts Payable of €3.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Capricor Therapeutics and its competitors. Capricor Therapeutics's current Accounts Payable is €3.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Capricor Therapeutics stock overvalued right now?
Capricor Therapeutics (LTS:0HTB) has a current Accounts Payable of €3.40 Mil. The current Accounts Payable is €3.40 Mil. Capricor Therapeutics' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Capricor Therapeutics (LTS:0HTB), the current Accounts Payable is €3.40 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Capricor Therapeutics Business Description

Other Exchanges CAPR:USA4LN2:Germany
Address 10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.